Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158:1450–61.

Article  PubMed  PubMed Central  Google Scholar 

Moran GW, Gordon M, Sinopolou V, et al. British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025. Gut. 2025;74(Suppl 2):s1–101.

Article  CAS  PubMed  Google Scholar 

Taleban S, Colombel JF, Mohler MJ, et al. Inflammatory bowel disease and the elderly: a review. J Crohns Colitis. 2015;9:507–15.

Article  PubMed  Google Scholar 

World Health Organization. Ageing and health. 2022. https://www.who.int/news-room/fact-sheets/detail/ageing-and-health. Accessed 31 Jan 2026.

Schwartz J, Stein DJ, Lipcsey M, et al. High rates of mortality in geriatric patients admitted for inflammatory bowel disease management. J Clin Gastroenterol. 2022;56:20–6.

Article  Google Scholar 

Fries W, Viola A, Manetti N, et al. Disease patterns in late-onset ulcerative colitis: results from the IG-IBD “AGED” study. Dig Liver Dis. 2017;49:17–23.

Article  PubMed  Google Scholar 

Rozich JJ, Dulai PS, Fumery M, et al. Progression of elderly-onset inflammatory bowel diseases: a systematic review and meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2020;18:2437-47.e6.

Article  PubMed  PubMed Central  Google Scholar 

Boyd T, Araka EB, Kochar B, et al. Differences in management and outcomes of older and younger adults with acute severe ulcerative colitis. J Crohns Colitis. 2024;18:570–7.

Article  PubMed  PubMed Central  Google Scholar 

Chowla NM, Tariq R, Hashash JG, et al. Outcome of acute severe ulcerative colitis in elderly patients. Gastroenterology. 2024;166:S-158 (abstract).

Article  Google Scholar 

Tejero Jurado R, El Fallous El Mraghid M, Carrillo Cubero B, et al. Impact of age and comorbidities on treatment outcomes and mortality in patients admitted for ulcerative colitis flares: a 20-year retrospective cohort study. J Crohns Colitis. 2025;19(Suppl 1):i1269 (abstract).

Article  Google Scholar 

Ollech J, Lev Kolnik R, Dotan I, et al. Comparison of disease severity, treatment, and outcomes in elderly and younger patients hospitalized with acute severe ulcerative colitis (ASUC). J Crohns Colitis. 2025;19(Suppl 1):i1529 (abstract).

Article  Google Scholar 

Favale A, Orrù V, Lutzu N, et al. Optimizing malnutrition risk detection in inflammatory bowel disease: a longitudinal analysis of serial nutritional screening tools. Nutrients. 2026;18:383.

Article  PubMed  PubMed Central  Google Scholar 

Gilbert T, Cordier Q, Polazzi S, et al. Combining the Hospital Frailty Risk Score with the Charlson and Elixhauser multimorbidity indices to identify older patients at risk of poor outcomes in acute care. Med Care. 2024;62:117–24.

Article  PubMed  Google Scholar 

Williams JG, Alam MF, Alrubaiy L, et al. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomized trial. Lancet Gastroenterol Hepatol. 2016;1:15–24.

Article  PubMed  PubMed Central  Google Scholar 

Laharie D, Bourreille A, Branche J, et al. Long-term outcome of patients with steroid-refractory acute severe ulcerative colitis treated with ciclosporin or infliximab. Gut. 2018;67:237–43.

Article  CAS  PubMed  Google Scholar 

Grob F, Häberling I, Novacek G, et al. Long-term outcome of ciclosporin and infliximab as rescue therapy in steroid-refractory acute severe ulcerative colitis. Inflamm Intest Dis. 2025;10:155–60.

Article  PubMed  PubMed Central  Google Scholar 

Okabayashi S, Yamazaki H, Tominaga K, et al. Lower effectiveness of intravenous steroid treatment for moderate-to-severe ulcerative colitis in hospitalized patients with older onset: a multicentre cohort study. Aliment Pharmacol Ther. 2022;55:1569–80.

Article  CAS  PubMed  Google Scholar 

Weber NK, Bruining DH, Loftus EV Jr, et al. Comparative outcomes of younger and older hospitalized patients with inflammatory bowel disease treated with corticosteroids. Inflamm Bowel Dis. 2013;19:2644–51.

Article  PubMed  Google Scholar 

Subhaharan D, Ramaswamy PK, Willmann L, et al. Older adults with acute severe ulcerative colitis have similar steroid non-response and colectomy rates as younger adults. World J Gastroenterol. 2023;29:2469–78.

Article  PubMed  PubMed Central  Google Scholar 

Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut. 1996;38:905–10.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vuyyuru SK, Alphonsus L, De Silva TA, et al. Day 3 Oxford criteria predict steroid non-response for acute severe ulcerative colitis in the post-biologic era. J Crohns Colitis. 2025;19:jjaf131 (in press).

Article  PubMed  PubMed Central  Google Scholar 

Mastoridou EM, Fousekis FS, Sakellariou XM, et al. The cardiovascular effects of inflammatory bowel disease therapy with biologics and small molecules: a comprehensive review. J Clin Med. 2025;14:6476.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Grillo TG, Silveira CFDSMP, Quaglio AEV, et al. Acute heart failure as an adverse event of tumor necrosis factor inhibitor therapy in inflammatory bowel disease: a review of the literature. World J Cardiol. 2023;15:217–28.

Article  PubMed  PubMed Central  Google Scholar 

ClinicalTrials.gov. Study NCT02770040. https://www.clinicaltrials.gov/study/NCT02770040. Accessed 20 Sept 2025.

Narula N, Marshall JK, Colombel JF. Systematic review and meta-analysis: infliximab or ciclosporin as rescue therapy in patients with severe ulcerative colitis refractory to steroids. Am J Gastroenterol. 2016;111:477–91.

Article  CAS  PubMed  Google Scholar 

Biancone L, Annese V, Ardizzone S, et al. Safety of treatments for inflammatory bowel disease: clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Dig Liver Dis. 2017;49:338–58.

Article  CAS  PubMed  Google Scholar 

Honap S, St-Pierre J, Colwill M, et al. Comparative effectiveness of tofacitinib versus upadacitinib for the treatment of acute severe ulcerative colitis. Clin Gastroenterol Hepatol. 2025;23:S1542-3565(25)00639-1 (in press).

Google Scholar 

Singh A, Goyal MK, Midha V, et al. Tofacitinib in acute severe ulcerative colitis (TACOS): a randomized controlled trial. Am J Gastroenterol. 2024;119:1365–72.

Article  CAS  PubMed  Google Scholar 

Gisbert JP, Chaparro M. Janus kinase inhibitors in the management of acute severe ulcerative colitis: a comprehensive review. J Crohns Colitis. 2025;19:jjaf021 (in press).

Article  PubMed  Google Scholar 

Garcia NM, Memel Z, Zou Y, et al. Upadacitinib is safe and effective in older adults: a real-world experience comparing safety and efficacy in younger versus older adults with inflammatory bowel disease. Dig Dis Sci. 2026. https://doi.org/10.1007/s10620-025-09647-y.

Article  PubMed  Google Scholar 

Alsaleh T, Mohammed A, Farooq A, et al. Upadacitinib versus tofacitinib in the management of ulcerative colitis: a systematic review and meta-analysis. Inflamm Intest Dis. 2025;11:29–42.

Article  PubMed  PubMed Central  Google Scholar 

Veyrard P, Pellet G, Laharie D, et al. Efficacy of induction therapy with calcineurin inhibitors in combination with ustekinumab for acute severe ulcerative colitis. Clin Gastroenterol Hepatol. 2023;21:1354-5.e2.

Article  CAS  PubMed  Google Scholar 

Gisbert JP, García MJ, Chaparro M. Rescue therapies for steroid-refractory acute severe ulcerative colitis: a review. J Crohns Colitis. 2023;17:972–94.

Article  PubMed  Google Scholar 

Vitali F, Rath T, Klenske E, et al. Long-term outcomes of cyclosporin induction and ustekinumab maintenance combination therapy in patients with steroid-refractory acute severe ulcerative colitis. Ther Adv Gastroenterol. 2023;17:17562848231218555.

Article  PubMed  PubMed Central  Google Scholar